Reducing API costs
We have formulated a number of APIs with our Super Refined™ excipients and found that in many cases a significantly higher percentage of API is retained over time compared to formulation with standard pharmaceutical grade excipients. This decreases the minimum efficient concentration required to produce the desired pharmacological effect over the shelf life of the product, therefore requiring less API per dose.
The removal of polar impurities reduces API/excipient interactions, thus minimising the presence of potentially problematic API degradation products.
Super Refined excipients have been demonstrated to outperform their standard pharmaceutical equivalents with regard to the stabilisation of certain APIs over significantly longer periods of time. Also with regard to the oxidative stability of the excipient itself, which has an effect on the overall stability of the drug formulation.
About cookies on this site